December 14th, 2023

As we prepare to bid farewell to another extraordinary year of collaboration and innovation within our vibrant life sciences sector, we are grateful for you, the individuals and organizations that comprise our outstanding ecosystem. This holiday season, we wish you rest and relaxation among family and friends and a happy and prosperous New Year!

– William, Lisa, Ryan, Joanna, Joanne, Wendy, Claire, and Johanna

Life Sciences BC seeks to raise the profile of our members and supporters, highlight their achievements, and promote BC's dynamic life sciences ecosystem. If you have news or a story to share, let us know.

You can find previous editions of BioLinks newsletters and other resources on our website at News/Publications.

Life Sciences BC News

Welcome to the final BioLinks newsletter of 2023 – and what an exciting, action-packed year it has been! While we will break for the holidays on Dec.15th, we look forward to returning in the New Year to continue sharing exciting news and events from LSBC and our community.  

This includes our 5th annual Career Connect Day on Jan. 26th, which brings life sciences employers, post-secondary students, and job seekers together for presentations, networking, and a job fair exhibition hall. Check out the participating companies and register here! 

You will also want to save the date for our 9th annual Access to Innovation Conference on Feb. 28th. This full-day, in-person conference brings together life sciences leaders from academia, research, health institutions, government, and industry for dialogue on sector policy, trends, and innovations. Check out our growing lineup of speakers and topics, and register here! 

LSBC was thrilled to be in attendance today as the province announced its approval of a business plan and funding for constructing a cutting-edge Clinical Support and Research Centre (CSRC) at the new St. Paul's Hospital, reinforcing BC's status as a growing global life sciences hub. Premier David Eby, Ministers Brenda Bailey (JEDI) and Adrian Dix (Health), Fiona Dalton, President & CEO of Providence Health Care and MLA Joan Phillip provided remarks at the announcement.

Providence Health Care and Providence Research operate several major research centres based at St. Paul's Hospital and other surrounding locations. Once complete, the center aims to translate scientific breakthroughs into practical healthcare applications, allowing for an integrated health campus. 

Aligning with BC's Life Sciences and Biomanufacturing Strategy under the StrongerBC Economic Plan, the project is expected to attract top scientific, research, and healthcare professionals, support emerging technologies, and help define the future of medicine and patient care in BC and beyond. Congratulations to everyone involved in this groundbreaking initiative! Read the press release here.

A big thank you to everyone who joined this week's Blakes Breakfast Speaking Series: Preparing for J.P. Morgan Week event! It was a dynamic morning filled with valuable and practical insights and strategies from those "in the know" on navigating the conference confidently and making the most of your experience.

Thanks to all who participated, including Joseph Garcia, Partner and leader of the Life Sciences Group at Blakes, our generous event sponsor. Additional speakers included Christian Barrow of J.P. Morgan, Ali Ardakani of Novateur Ventures and our Board Chair, Allison Gaw of Amplitude Ventures, Alejandra Balaguer of Life Science Nation, Lila Taylor of Demy-Colton, Mackensie Vernetti of Biotechnology Innovation Organization (BIO), and Wendy Hurlburt. Each brought their unique perspective and expertise to the conversation. Attendees also enjoyed engaging company presentations by Tom Reeves of Ripple Therapeutics and Ian McBeath of Naegis Pharmaceuticals.

Over 50 BC companies will be at this year's JPM Week —a fantastic representation of our province! If you're attending, let us know so we can include you in our activities. We hope to see you there! Click here to send Life Sciences British Columbia a meeting request in the BIO partnering system!

*Conference hack!* BIO and Novateur Ventures are providing a "Guide to JPM" app for iPhone and Android. This free app helps you decide which receptions and educational opportunities to prioritize during JPM Week. Check it out here.

We were delighted to attend this week’s Alpha-9 Theranostics holiday reception and open house, which included a fascinating company presentation and tour of their labs!

Thank you to David Hirsch, Marlo Mae Manning, and the Alpha-9 team for hosting this festive and informative event!

Member Highlights 

The University of BC has released its Year in Review 2023, highlighting this year's breakthrough research, program expansions, the exciting launch of Canada's Immuno-Engineering and Biomanufacturing Hub, and its future plans. Read it here.

The Vancouver Canucks have selected WELL Health Technologies as the Official Medical Services Provider to the team! This partnership heralds a new era in healthcare for elite athletes, providing them with leading-edge diagnostic imaging, sports cardiology and pain management services designed to enhance the players' overall health and performance. Learn more about this exciting collaboration here. WELL Health CEO Hamed Shahbazi was also recently featured in an interview with Cantech Letter, discussing the future of digital healthcare, including AI. Watch it here. 

Gandeeva CEO Sriram Subramaniam, was featured in Nature Methods, discussing the future of structural biology, including the role of generative AI and experimental methods such as cryo-EM. Read it here. 

Cynthia Pussinen of Sernova was recently featured in a BioPharm International article discussing raw material variability sources and the strategic approaches to overcome challenges in the production of cell therapies. Read it here. 

adMare BioInnovations has welcomed 22 influential life science sector leaders - including several LSBC members - to Cohort VI of the adMare Academy Executive Institute, an 8-month talent development program. Learn more and see the list of participants here.

Michael Smith Health Research BC has announced its 2023 Convening & Collaborating (C2) & Reach award recipients! Learn more about these deserving individuals and the various research areas they'll be investigating here. 

New Members

Ryan CPA provides an integrated suite of federal, state, local, and international tax services on a multi-jurisdictional basis.

Welcome to the LSBC community!

Industry Highlights

In 2022-2023, PacifiCan completed its first full year in operation and recently shared highlights from its Departmental Results Report, including opening seven new offices across the province and investing in BC businesses, innovators, and communities. Read it here.

Canada's National Research Council, in partnership with the Office of the Chief Science Officer, is hosting its virtual 2024 Celebrating the Success of Women in STEM Symposium: women, sustainability and climate solutions in Feb. 2024. The event will feature a virtual poster session, allowing participants to explore research findings and connect with fellow attendees. Learn more here.

Kudos

Congratulations to Dr. Allen Eaves, President and CEO of STEMCELL Technologies, and Dr. Connie Eaves, who have been recognized for their support for the BC Cancer Foundation with the newly named Eaves Stem Cell Assay Laboratory at BC Cancer's L. J. Blackmore Cancer Research Centre. This distinction underscores their extraordinary fifty-year legacy and pivotal role in revolutionizing global cancer research and treatment. Learn more here. (Photo credit: BC Cancer Foundation)

Kudos to Miranda Lam from Acuitas Therapeutics, Deputy Minister to the Premier Shannon Salter, and all appointees of this year's King's Counsel in British Columbia. This prestigious recognition, bestowed by the Cabinet, acknowledges lawyers who exhibit professional integrity, good character, and excellence in legal practice. It highlights their distinguished counsel and outstanding contributions to the legal profession and the broader community. For further details, refer to the announcement by the Attorney General, available here.

Congratulations to the 19 recipients of CIHR’s 2023 Personnel Awards for Black Scholars, including UBC’s Ismália De Sousa whose work focuses on young women diagnosed with strokes. Learn more about these scholars' outstanding work and see the complete list of recipients here.

Kudos to the Vancouver Coastal Health Authority (Vancouver Coastal Health Research Institute (VCHRI) and Providence Health Care Research Institute), ranked fourth in Research Infosource Inc.’s annual ranking of Canada’s top research hospitals! Learn more here.

People on the Move

Nancy Davidson, M.D., has joined the Zymeworks Board of Directors. Dr. Davidson is an oncologist and researcher with decades of breast cancer biology and treatment expertise.

Applications Open

AccelerateIP (AIP), developed in collaboration with New Ventures BC and Innovate BC, has officially launched in BC, the Yukon, Nunavut, and the Northwest Territories! As a proud delivery partner, LSBC invites startups to apply for this comprehensive program, providing unmatched intellectual property (IP) education and strategy support. AIP's new website details the program, eligibility requirements, and the opportunity to kickstart your startup's journey. Check out the press release for more information.

You can find a recent IP Assist + Accelerate IP Info Session recording here.

A large cohort of UVic biochemistry and microbiology co-op students is gearing up to work for the May to August 2024 term. Some students are available to work for 8 or 12 months. If you or a colleague would like to bring your employment opportunities to the attention of UVic students, please send your job descriptions to scico@uvic.ca to post the job to the co-op portal.

Canada's High Commission in London is partnering with NRC IRAP to support Canadian companies returning to the UK on the week of Feb. 26, 2024. This mission follows the $32M Canada-UK Memorandum of Cooperation on Biomanufacturing signed on June 8th, focusing on bilateral partnerships for innovative and sustainable biologics and therapies. The visit's main objective is to connect companies with potential UK R&D/co-innovation partners, fostering collaboration for an upcoming funding competition next spring. Find more details on the mission here. The closing date is Dec. 29. Reach out with questions here.

We invite you to explore our expanded list of current life sciences application opportunities by clicking the button below.

Upcoming LSBC events and programs at-a-glance

Jan. 16/17 - LSBC, in partnership with Biotech Primer, is pleased to present BioBasics 201: Targeted Biologics for the Non-Scientist, a follow-up to BioBasics 101.



Jan. 26 - Attention life sciences employers, post-secondary students, and job seekers! This dynamic, full-day event brings together life sciences sector employers, along with current and future job seekers, to explore a world of opportunities. 

Feb. 28 - Join us for our 9th Annual Access to Innovation conference. This full-day gathering welcomes life sciences leaders and trailblazers from academia, research, health institutions, government, and industry.

We look forward to seeing you in the New Year!

Wendy and the LSBC team

Numinus Congratulates MAPS on its Application to the FDA for MDMA-Assisted Therapy for PTSD

Numinus Wellness Inc., a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, congratulates the Multidisciplinary Association of Psychedelics Studies for its submission of a new drug application to the U.S. Food and Drug Administration for MDMA (midomafetamine capsules) used in combination with psychological intervention, which includes psychotherapy, or talk therapy, and other supportive services provided by a qualified healthcare provider... READ MORE

United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger

United Therapeutics Corporation and Miromatrix Medical Inc. announced that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc., has successfully completed the previously announced tender offer to acquire all outstanding shares of Miromatrix... READ MORE

UBC Researchers Develop Model to Accurately Predict Risk of C-Section Birth

Researchers at the UBC Faculty of Medicine have developed a computer model that accurately predicts a woman’s risk of caesarean birth when they are first admitted to hospital. The model, created by Dr. Patricia Janssen and her team, analyzes patient information that nurses routinely gather at hospital admission, such as maternal age, gestational age, and height....READ MORE

Vesna Sertić Joins Santis Health to Help Clients Navigate Alberta’s Evolving Health Care Landscape

Santis Health continues to expand its Western Canada Practice with the addition of Vesna Sertić as a Senior Consultant. Vesna’s addition comes at an important period of change and restructuring within the Alberta health system. Equipped with an impressive Conservative network across the country and insights into Alberta’s provincial government, Vesna will leverage this expertise to support clients in understanding what’s next for health in the province... READ MORE

Funding Paves the Way for Innovative Wastewater Surveillance Program in British Columbia

A new initiative, dubbed SAFEGUARD, aims to transform monitoring for viruses and other pathogens in British Columbia, offering early and enhanced surveillance to better prepare the province and Canada for future public health challenges... READ MORE

Eupraxia Pharmaceuticals Announces Positive Clinical Data in EP-104GI RESOLVE Trial

Eupraxia Pharmaceuticals Inc., a Phase 2 clinical-stage biotechnology company, announced positive clinical data from its Phase 1b/2a RESOLVE trial, which is evaluating safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis... READ MORE

Research Tracks Severity—and Rise—of Spinal Cord Injuries From Older Adult Falls

Numaira Obaid, a postdoctoral fellow in SFU’s Surrey-based Neurospine Biomechanics Lab, is investigating how age-related degeneration impacts geriatric spinal injuries. She hopes her findings will help develop better fall prevention strategies... READ MORE

Catalyzing Pathways From Evidence to Impact

Health research teams across British Columbia are putting knowledge into action with funding awarded by Michael Smith Health Research BC. The Convening & Collaborating and Reach funding programs are enabling health researchers to foster collaboration, disseminate and implement evidence, and increase the impact of their research — ultimately improving the health of people and communities in BC... READ MORE

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2023... READ MORE

WEX Pharmaceuticals Inc. Commences Its Quantitative Sensory Testing Clinical Trial Evaluating the Impact of Halneuron® on Healthy Volunteers’ Sensory Perceptions

WEX Pharmaceuticals Inc., a biotechnology company developing Halneuron® for pain, announced that it has commenced its Quantitative Sensory Testing clinical trial and is actively recruiting participants into this clinical trial. The trial is being conducted in the Netherlands on 25 healthy volunteers, where each volunteer will receive two different doses of Halneuron... READ MORE

LifeLabs Introduces Seven Days a Week Access to Diagnostic Services in Vaughan

LifeLabs, Canada’s leading provider of medical diagnostic services, is catering to the growing healthcare needs of Vaughan residents with the grand opening of a new Patient Service Centre that’s open seven days a week. Located at 270 Purple Creek Rd Suite 201 in Vaughan, this marks a significant milestone as the first diagnostic lab in the rapidly developing area and 5th location within the City of Vaughan... READ MORE

Filament Health Announces Adjournment Of Special Meeting

Filament Health Corp. announces that the special meeting of its securityholders to be held this Monday, December 11, 2023 at 9:30 a.m. to approve, among other things, the Company’s proposed arrangement under Part 9, Division 5 of the Business Corporations Act has been adjourned. The adjourned Special Meeting will be reconvened on Monday, December 18, 2023, at 9:30 a.m... READ MORE

Eupraxia Pharmaceuticals Announces Clinical and Corporate Update

Eupraxia Pharmaceuticals Inc., a Phase 2 clinical-stage biotechnology company, announced updates for its two clinical programs, EP-104IAR, its lead drug candidate in development for the treatment of knee osteoarthritis, and EP-104GI, a high-potential product candidate in development for the treatment of eosinophilic esophagitis... READ MORE

ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

Seagen Inc. announced that clinically meaningful progression-free survival was observed in a Phase 2 study evaluating the antibody-drug conjugate ADCETRIS® in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine as first-line treatment for early and advanced stage classical Hodgkin lymphoma... READ MORE

Vancouver Coastal Health Research Institute is Among Canada’s Leading Hospital-Based Research Institutes

In a recent announcement, Research Infosource Inc., a leading Canadian research, consulting and publishing firm, has revealed its annual ranking of Canada’s top 40 research hospitals. Vancouver Coastal Health Authority (Vancouver Coastal Health Research Institute and Providence Health Care Research Institute), proudly occupies the fourth position, with $168.8 million in research funding for the year 2022... READ MORE

New Maternity Clinic Opens its Doors to Expectant Families in the Central Okanagan

Expectant parents and babies in the Central Okanagan will have improved access to services and supports through the new Central Okanagan Maternity Clinic. The clinic is a partnership between Interior Health, the Central Okanagan Division of Family Practice and family physicians, with funding from the Ministry of Health... READ MORE

Boehringer Ingelheim Canada and Community-based Clinics Join to Revolutionize Cardiovascular Care in Ontario

In an innovative partnership, Boehringer Ingelheim (Canada) Ltd. has joined forces with established cardiology clinics across Ontario to transform community care for cardiovascular patients through a cardiovascular optimization program, emphasizing accessibility and collaboration... READ MORE

United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2024

United Therapeutics, a public benefit corporation, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2024. This award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The list of awards was announced on December 6, 2023, is available on Newsweek’s website, and recognizes the top 600 most responsible companies in the United States, spanning 14 industries... READ MORE

Avantor® Hosts Investor Day, Announces New Strategic Operating Model to Drive Growth and Productivity

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the biopharma and healthcare, education and government, and advanced technologies industries, will host an Investor Day on December 8th to discuss the company’s strategic growth plans. During the event, Avantor will outline its plans to transform the business by implementing a new operating model and advancing a multi-year cost optimization initiative... READ MORE

WELL Health Selected by the Vancouver Canucks as Official Medical Services Provider

WELL Health Technologies Corp., a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare providers and their patients globally, and Canucks Sports & Entertainment are pleased to announce that the Vancouver Canucks have selected WELL as the Official Medical Services Provider to the team... READ MORE

TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

Seagen Inc. announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®). The combination showed a statistically significant improvement in progression-free survival in patients with unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive breast cancer who had been previously treated, compared to those who received placebo... READ MORE

Filament Health Announces Signing Of Definitive Agreement for Convertible Note Financing, Closing of C$900,000 Non-Brokered Private Placement Financing, Founder-Led Note Offering, And Other Updates Related To Proposed Business Combination

Filament Health Corp., a clinical‐stage natural psychedelic drug development company, announces that, further to its press release dated November 23, 2023, the Company has entered into a definitive securities purchase agreement with Helena Global Investment Opportunities... READ MORE

World-Renowned Researchers Drs. Connie & Allen Eaves’ 50-Year Legacy Honoured with Dedicated BC Cancer Clinical Service Lab

The BC Cancer Foundation is proud to announce the unveiling of the newly named Eaves Stem Cell Assay Laboratory at BC Cancer’s L.J. Blackmore Cancer Research Centre. This announcement further solidifies the remarkable fifty-year legacy of Drs. Connie and Allen Eaves in transforming global cancer research and treatment.... READ MORE

AstraZeneca Canada Inc. is a science-led biopharmaceutical company pushing the boundaries of science to deliver life-changing medicines. The company employs roughly 900 people in Canada who work to research, develop and market innovative medicines. AstraZeneca Canada was designated a global Clinical Hub for oncology & immuno-oncology clinical studies. We are currently leading global oncology clinical studies in lung, head and neck cancer.

The future of treatment for many of today’s diseases lies in uncovering mechanisms that are newly emerging or are still to be discovered. We believe the best way to help patients is to focus on breakthrough science to discover these mechanisms and develop novel, targeted therapies that interact with them. Our focus is on the following core therapy areas: Cardiovascular, Renal and Metabolic diseases (CVRM); Oncology; and Respiratory & Immunology. AstraZeneca has 83,500+ employees and an active R&D presence in more than 60 countries across the globe. LEARN MORE

New Clinical Support, Research Centre to be Built Next to New St. Paul’s Hospital

People in B.C. will benefit from advanced patient care resulting from cutting-edge research and integrated health care as the Province approves the business plan and funding for the construction of a state-of-the-art Clinical Support and Research Centre (CSRC) near 1002 Station St, directly adjacent to the new St. Paul’s Hospital... READ MORE

More Organizations Sign on to Canada’s Voluntary AI Code of Conduct, Including CGI and IBM

Recent advances in artificial intelligence (AI) technology are benefiting society in many ways, including in improving supply chain management, enhancing health care and precision medicine, and helping tackle environmental sustainability challenges. These advances, however, have also reaffirmed the urgency of ensuring that AI systems, particularly advanced generative AI systems, are developed and used safely. That is why the Government of Canada recently launched the Voluntary Code of Conduct on the Responsible Development and Management of Advanced Generative AI Systems... READ MORE

Industry Partnership Manager

Working under broad directions of the Executive Director of CIEBH, the Industry Partnership Manager will develop and mobilize academic and hospital discoveries originating from the University and its Affiliated Hospitals, through fostering sponsored research, supporting entrepreneurship, developing and implementing knowledge mobilization plans, engaging with researchers and industry, and conducting evaluations...LEARN MORE

Director, Data Science and Pharmacokinetic Modeling

Eupraxia is seeking a highly skilled and experienced Director of Data Science and Pharmacokinetic Modeling to lead our programs designed to deliver appropriate, robust and defensible data in a readily understandable manner. They will also responsible for preparing and maintaining related documentation for relevant due diligence exercises, ensuring the content is comprehensive and structured to make the most complex issues and analyses accessible to lay personnel...LEARN MORE

Senior Manager/Associate Director, Project Management

Alpha-9 is seeking a Senior Manager/Associate Director of Project Management, to lead program management activities for several early-stage radiopharmaceutical cancer therapeutics from IND-enabling studies through clinical trials. This role will ensure organizational alignment and oversee program execution, as well as foster team building and a collaborative environment and is responsible for working closely with team members to forecast key milestones and decision points and deliver program objectives...LEARN MORE

Associate/Scientist, Surface Plasmon Resonance

Alpha-9 is seeking an Associate Scientist to join our Biology group. The ideal candidate will have extensive hands-on experience and skills in Surface Plasmon Resonance, especially for characterization of molecular interactions between target of interest and radiopharmaceutical ligands (especially for small molecules or peptide-based molecules). Experience with membrane protein purification is a plus, but not mandatory...LEARN MORE

Research Associate, Preclinical

NanoVation Therapeutics is looking for a collaborative and solution-focused Research Associate, Preclinical, to join our team. Reporting to the Scientist II, Preclinical, the Research Associate, Preclinical will work closely with the Preclinical Team and will be responsible for executing in vivo research focusing on flow cytometry in support of our research goals and plans...LEARN MORE

Research Associate 2, Biology (In Vivo)

We are seeking a Research Associate 2, Biology to join our In Vivo Pharmacology team. The incumbent will provide technical In Vivo support for our preclinical drug discovery projects. The successful candidate will conduct In Vivo pharmacology experiments to characterize the pharmacokinetics, efficacy and safety of compounds...LEARN MORE

Account Manager, proXimity

Reporting to the VP, proXimity, you possess a unique blend of clinical trial industry knowledge and general business acumen; a hard worker striving to enhance the experience of our existing customers and drive new business within our current customer base forward. You are part of the proXimity team ensuring we are reaching our business goals and targets for the proXimity software and ensuring the current proXimity customers are receiving an exception level of customer service...LEARN MORE

Clinical Trial Assistant

The clinical trial assistant supports various clinical operations tasks, including developing trackers, compiling essential documents for regulatory submissions, coordinating data evaluation, managing clinical program files, creating site-facing forms, documenting meeting minutes, participating in teams/committees, conducting literature research, tracking budgets and contracts, and serving as the primary contact for study-related communication with sites, vendors, and service providers...LEARN MORE

Senior Clinical Study Manager, Clinical Operations

The Senior Clinical Study Manager is responsible for the oversight, execution and success of Eupraxia clinical studies. The Study Manager works cross-functionally with internal functional leads and external contract research organizations (CROs) to ensure that studies are completed to agreed standards, timelines and budget. The role will develop and support the work of Eupraxia’s clinical operations across a range of products and in accordance with company policies, procedures and culture...LEARN MORE

Senior Program Manager

The Senior Program Manager is a pivotal leadership role within our organization. This individual will be responsible for the successful global development, registration, and launch of pharmaceutical products. This role involves managing a matrix team and providing oversight for all key functions and activities, ensuring alignment with our strategic objectives...LEARN MORE



Lead Clinical Research Associate, Clinical Operations

The candidate will oversee and ensure the appropriate operation and completion of clinical trials in selected sites by assessing the trial site and applicable personnel on an ongoing basis, adhering to protocol regulatory requirements, good clinical practice regulations, and standard operating procedures. They will also ensure compliance with the patient-consent processes, verifying the receipt, handling, accounting, storage conditions, and availability of clinical products under investigation...LEARN MORE

Senior Project Manager

The senior project manager manages concurrent projects, ensuring adherence to budget, resource allocation, scope, and schedule, utilizing formal Project Management methods, collaborating with cross-functional teams for stakeholder buy-in, while proactively assessing and addressing risks...LEARN MORE

Senior/Principal Scientist, Preclinical Pharmacology

The ideal candidate is a curious and committed individual, ready for the opportunity to transform the way people living with cancer can be treated. We are in search of team members who work collaboratively with a diverse group of colleagues, respectfully engaging one another while collectively and inclusively tackling any challenges we may face. We are building an exciting and fast paced company passionate about discovering and developing tomorrow’s most innovative cancer therapies...LEARN MORE

Senior Director, Medical Affairs

The Director, Medical Affairs will be responsible for defining and implementing KOL strategies to develop and maintain positive KOL endorsement and product champions for Eupraxia in OA diseases. The role will also be responsible for leading Eupraxia medical education initiatives and conference activities...

LEARN MORE

Stay current by subscribing to this and our events newsletter!

Follow LSBC on Social Media!